Allopurinol to Prevent Cirrhosis Related Morbidities
Status:
Not yet recruiting
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
The study aims to compare the potential benefit of allopurinol in reducing the risk of
developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma,
and improving survival. Furthermore, the study aims to evaluate their impact on parents'
related quality of life